Jan 25 (Reuters) - GENSIGHT BIOLOGICS SA:
* GENSIGHT BIOLOGICS REPORTS â‚¬55 MILLION 2017 YEAR-END CASH POSITION AND PROVIDES CORPORATE UPDATE
* TOPLINE RESULTS OF REVERSE AND RESCUE ARE EXPECTED IN APRIL AND 3Q 2018, RESPECTIVELY.
* REFLECT, PHASE III CLINICAL TRIAL: FIRST PATIENT IS EXPECTED TO BE TREATED IN 1Q 2018 IN US.
* PIONEER PHASE I/II CLINICAL TRIAL: FIRST PATIENT IS EXPECTED TO BE TREATED IN 1Q 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 